Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:HEB
CUSIPN/A
Phone+1-407-2718516
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1,391.11%
Return on Equity-49.30%
Return on Assets-32.57%
Miscellaneous
EmployeesN/A
Outstanding Shares46,200,000
Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions
What is Hemispherx BioPharma's stock symbol?
Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."
How were Hemispherx BioPharma's earnings last quarter?
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) issued its quarterly earnings results on Wednesday, May, 16th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter. The specialty pharmaceutical company earned $0.06 million during the quarter. Hemispherx BioPharma had a negative net margin of 1,391.11% and a negative return on equity of 49.30%. View Hemispherx BioPharma's Earnings History.
Are investors shorting Hemispherx BioPharma?
Hemispherx BioPharma saw a decrease in short interest in May. As of May 31st, there was short interest totalling 635,692 shares, a decrease of 1.3% from the May 15th total of 644,205 shares. Based on an average trading volume of 506,552 shares, the short-interest ratio is currently 1.3 days. Approximately 1.4% of the shares of the stock are sold short. View Hemispherx BioPharma's Current Options Chain.
Who are some of Hemispherx BioPharma's key competitors?
Some companies that are related to Hemispherx BioPharma include BELLUS Health (BLU), Medicenna Therapeutics (MDNA), Destiny Pharma (DEST), NovaBay Pharmaceuticals (NBY), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), OptiBiotix Health (OPTI), Scancell (SCLP), Synthetic Biologics (SYN), DiaMedica Therapeutics (DMA), Antibe Therapeutics (ATE), Biopharmx (BPMX), Realm Therapeutics (RLM), Ceapro (CZO) and Nuvo Pharmaceuticals (NRI).
Who are Hemispherx BioPharma's key executives?
Hemispherx BioPharma's management team includes the folowing people:
- Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 65)
- Mr. Adam Pascale, CFO & Chief Accounting Officer (Age 70)
- Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 67)
- Mr. Wayne S. Springate, Sr. VP of Operations (Age 47)
- Dr. David R. Strayer, Chief Scientific Officer & Medical Director (Age 72)
Has Hemispherx BioPharma been receiving favorable news coverage?
News articles about HEB stock have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Hemispherx BioPharma earned a coverage optimism score of 0.09 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 47.02 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Hemispherx BioPharma's major shareholders?
Hemispherx BioPharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (7.18%). Company insiders that own Hemispherx BioPharma stock include Adam Pascale, David R Strayer, Stewart Appelrouth, Thomas K Equels and Wayne S Springate. View Institutional Ownership Trends for Hemispherx BioPharma.
How do I buy shares of Hemispherx BioPharma?
Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hemispherx BioPharma's stock price today?
One share of HEB stock can currently be purchased for approximately $0.33.
How big of a company is Hemispherx BioPharma?
Hemispherx BioPharma has a market capitalization of $14.21 million.
How can I contact Hemispherx BioPharma?
Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.
MarketBeat Community Rating for Hemispherx BioPharma (HEB)
MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe HEB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEB will underperform the S&P 500 over the long term. You may vote once every thirty days.
